Navigation Links
S1 Biopharma Doses First Patients in Phase 2a Clinical Trial of Lorexys in Premenopausal Women with HSDD
Date:7/29/2013

JERSEY CITY, N.J., July 29, 2013 /PRNewswire/ -- S1 Biopharma, Inc., a developer of first-in-class drugs for sexual dysfunction in women and men, today announced enrollment and dosing of premenopausal women with hypoactive sexual desire disorder (HSDD) in the Phase 2a clinical trial of its leading drug candidate Lorexys (S1P-104).  

"The initiation of this study marks a significant milestone for S1 Biopharma as we advance Lorexys' clinical development," said Nicolas G. Sitchon, chief executive officer of S1 Biopharma. "Despite significant effort over many years, there are no FDA-approved treatments for women with HSDD. We believe Lorexys may provide the first safe and effective treatment option for those whose lives and the lives of their partners are affected by the disorder. By restoring the balance of the key neurotransmitters that regulate sexual desire in the brain we expect that Lorexys will help women with sexual desire and arousal disorders regain a healthy sexual life."

The leading scientific model of the regulation of sexual desire in the brain is the Kinsey dual control model. It explains that sexual inhibition and sexual excitation are kept in balance by activating and inhibiting neurotransmitters including serotonin, norepinephrine and dopamine.

"Lorexys, which is a first-in-class drug for HSDD, was formulated by identifying the two psychiatric medications, bupropion and trazodone, that, when combined in a precise, proprietary ratio, would modulate the activity of these neurotransmitters, neutralize the monoamine modulators' side effects and maximize beneficial effects on sexual function," said Robert E. Pyke, M.D., Ph.D., chief medical officer of S1 Biopharma. "Pilot data supported positive effects, unlike other serotonergic agents or combinations studied in our early drug development. S1P-205,
'/>"/>

SOURCE S1 Biopharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
2. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
3. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
4. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
5. Genesis Biopharma Announces Termination of Previously Announced Proposed Public Offering
6. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
7. S1 Biopharma Expands Focus to Include Male Sexual Health
8. New Study Details Foreign Efforts To Lure Biopharmaceutical Companies
9. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
10. Cell Therapeutics Aequus BioPharma Validates its Proprietary GlycoPolymer Technology for the Extension of the Half-life of Therapeutic Protein Drugs
11. Galena Biopharma, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015  Now available for sale, The Armor1 Ankle ... prevents ankle sprains by cushioning the ankle from an ... around the outside of any shoe type and allows ... still offering protection against sprains. With customers in physical ...
(Date:1/23/2015)... JUNCTION, N.J. , Jan. 23, 2015  CytoSorbents ... company commercializing its CytoSorb® extracorporeal cytokine adsorber to ... patients, announced the receipt of $385,642, net of ... participant of the Technology Business Tax Certificate Transfer ...
(Date:1/22/2015)... a privately held medical device company, announced today that ... ITOCHU Corporation (Tokyo Stock Exchange TYO: 8001) to sell ... cancer in Japan . ViewRay,s technology, ... only MRI-guided radiation therapy system that images and treats ...
Breaking Medicine Technology:The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2
(Date:1/22/2015)... PA (PRWEB) January 22, 2015 Woodloch Pines, ... Mountains, has been selected by TripAdvisor as the number one ... the 6th best in the world for their annual Travelers’ ... online travel community . The website is home to millions ...
(Date:1/22/2015)... January 22, 2015 Padre Murphy's and Owner ... of Pro Player Health Alliance (PPHA). The PPHA's ... in getting everyone, including NFL greats, treated for obstructive sleep ... leading groups supporting the cause in the valley. The most ...
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method ... lean muscle by up to 30lbs in less than 12 ... HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , “Our ... scientific diet formula that allows the body to pack on ...
(Date:1/22/2015)... EAGAN, Minn. (PRWEB) January 22, 2015 Blue ... discover those Minnesotans who exemplify what it means to “Live ... a chance for people to share their stories about how ... adversity or simply inspired others by living in the moment. ...
(Date:1/22/2015)... The federal court overseeing thousands of vaginal ... Southern District of West Virginia has upheld a $2 million ... bellwether trial. In an Order dated January 21st, the Court ... that C.R. Bard had not proven a miscarriage of justice. ...
Breaking Medicine News(10 mins):Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4
... 11 The Substance Abuse and,Mental Health Services ... Survey on Drug Use and Health (NSDUH) indicate,3.1 ... to 25 have abused non-prescription,over-the- counter (OTC) cough ... once,in their lifetime. This announcement and the data ...
... announced,today that a new generic prescription drug program will ... drugstores., The program offers a 30-day supply of ... The medicines on the list include antibiotics and drugs,that ... digestive issues., There are no forms to fill ...
... system should fight tumors, researchers say , , FRIDAY, ... fight ovarian and breast cancer are in the ... safety and effectiveness, researchers report. , The vaccine ... an assistant professor at the University of Pennsylvania,s ...
... aging and the declining health,status of the 78 ... in the United States, U.S. Preventive Medicine, Inc. ... years ahead., "According to a recent Forrester ... include wellness and disease management,programs in their health ...
... the ... BOLINGBROOK, Ill., Jan. 11 The first new ... open its doors on Monday,January 14. After three years ... reviews from the Illinois,Department of Public Health and is ...
... to make sure people are adequately informed about the ... trial can be field-tested for effectiveness as vigorously as ... Johns Hopkins bioethicist suggests. , Informed consent, ... by which potential research subjects are asked to decide ...
Cached Medicine News:Health News:Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on New SAMHSA Study On Cough Medicine Abuse 2Health News:Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on New SAMHSA Study On Cough Medicine Abuse 3Health News:Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on New SAMHSA Study On Cough Medicine Abuse 4Health News:Hy-Vee Unveils New Generic Drug Program 2Health News:Vaccines for Ovarian and Breast Cancer in Early Trials 2Health News:Vaccines for Ovarian and Breast Cancer in Early Trials 3Health News:U.S. Preventive Medicine(R) Predicts Robust Growth Ahead 2Health News:Adventist Bolingbrook Hospital Opens to the Public 2Health News:Ways to improve informed consent are testable, study says 2
... the C-terminal cleavage product produced during processing ... insulin molecule. Although the C-peptide of insulin ... liver or extra-renal metabolism and therefore has ... [1]. In addition, C-peptide assays may be ...
... C19 steroid, is one of the most ... males, testosterone is secreted primarily by the ... from peripheral conversion of androstenedione [2]. In ... over 50% of serum testosterone is derived ...
... Thyroid-stimulating hormone (TSH) is a 32 kDa ... the anterior pituitary gland [1]. The structure ... of the pituitary and placental gonadotropins, consisting ... identical between these hormones and a unique ...
... (T3) is produced primarily by 5-monodeioination of ... thyroid gland, T3 production occurs at a ... for T4. Release of T3 from the ... micrograms/day as compared to 80-100 micrograms/day for ...
Medicine Products: